methoxy-morpholinyl-doxorubicin has been researched along with Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Aujay, MA; Gavrilyuk, J; Gu, C; Hamdy, OM; Holda, MK; Holte, D; Jun Lee, D; Laysang, A; Lee, C; Lin, B; Lyssikatos, JP; Purcell, JW; Pysz, MA; Sandoval, J; Sarvaiya, H; Sisodiya, V; Swinney, Z; Tchelepi, RB; Valdiosera, AM; Williams, S | 1 |
| Chen, CS; Lu, H; Waxman, DJ | 1 |
| Baldwin, A; Huang, Z; Jounaidi, Y; Waxman, DJ | 1 |
| Adams, L; Bissett, D; Breda, M; Cassidy, J; Kaye, SB; Pacciarini, MA; Poggesi, I; Strolin-Benedetti, M; Vasey, PA; Wilson, P | 1 |
| Cooper, N; Gerber, M; Narang, PK; Nicol, SJ; O'Brien, SM; Ratain, MJ; Schilsky, RL; Skoog, LA; Vogelzang, NJ | 1 |
| Bauer, J; Cavalli, F; D'Incalci, M; de Jong, J; Domenigoni, L; Ghielmini, M; Naegele, H; Pacciarini, MA; Rossi, S; Sessa, C; Zucchetti, M | 1 |
| de Vries, EG; Fokkema, E; Groen, HJ; Spinelli, R; Uges, DR; Valota, O; van Oosterom, AT; Verweij, J | 1 |
4 trial(s) available for methoxy-morpholinyl-doxorubicin and Neoplasms
| Article | Year |
|---|---|
Phase I clinical and pharmacokinetic study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762).
Topics: Adult; Aged; Doxorubicin; Female; Humans; Liver; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 1995 |
Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Doxorubicin; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Neoplasms | 1997 |
Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243).
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Area Under Curve; Colonic Neoplasms; Doxorubicin; Female; Half-Life; Humans; Leukocyte Count; Male; Middle Aged; Neoplasms; Neutrophils; Pancreatic Neoplasms | 1999 |
A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antiemetics; Area Under Curve; Cohort Studies; Doxorubicin; Drug Administration Schedule; Humans; Male; Middle Aged; Neoplasms | 2000 |
3 other study(ies) available for methoxy-morpholinyl-doxorubicin and Neoplasms
| Article | Year |
|---|---|
Evaluation of PNU-159682 antibody drug conjugates (ADCs).
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Humans; Immunoconjugates; Mice, Inbred NOD; Mice, SCID; Neoplasms | 2020 |
Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Doxorubicin; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Humans; Ifosfamide; Mice; Neoplasms; Retroviridae; Transfection | 2009 |
Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Coculture Techniques; Cyclophosphamide; Cytochrome P-450 Enzyme System; Dacarbazine; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Activation; Female; Genetic Therapy; Ifosfamide; Inhibitory Concentration 50; Ketoconazole; Liver; Male; Microsomes, Liver; Models, Chemical; Neoplasms; Procarbazine; Prodrugs; Rats; Tamoxifen; Time Factors; Troleandomycin; Tumor Cells, Cultured | 2003 |